Mark R Kobayashi, MD | |
Uci Medical Center, 101 The City Drive South, Orange, CA 92868 | |
(714) 456-8978 | |
Not Available |
Full Name | Mark R Kobayashi |
---|---|
Gender | Male |
Speciality | Plastic And Reconstructive Surgery |
Experience | 40 Years |
Location | Uci Medical Center, Orange, California |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1518047729 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208200000X | Plastic Surgery | 000000A43597 (California) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
University Of California Irvine Medical Center | Orange, CA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Regents Of The University Of California | 2860473873 | 10 |
News Archive
The 5-4 ruling says some closely held corporations cannot be forced to provide services that are at odds with the owners' religious beliefs.
More than 80,000 people undergo resection of a pulmonary tumor each year, and currently the only method to determine if the tumor is malignant is histologic analysis. A new study reports that a targeted molecular contrast agent can be used successfully to cause lung adenocarcinomas to fluoresce during pulmonary surgery.
Shire plc and Parion Sciences, Inc. have announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults, with the opportunity for Parion to co-fund.
Diets with high amounts of whole grains may help achieve significant weight loss, and also reduce the risk of chronic diseases such as diabetes and cardiovascular disease, according to a team of Penn State researchers at University Park and the College of Medicine.
› Verified 7 days ago
Entity Name | Regents Of The University Of California |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1336171818 PECOS PAC ID: 2860473873 Enrollment ID: O20040526000700 |
News Archive
The 5-4 ruling says some closely held corporations cannot be forced to provide services that are at odds with the owners' religious beliefs.
More than 80,000 people undergo resection of a pulmonary tumor each year, and currently the only method to determine if the tumor is malignant is histologic analysis. A new study reports that a targeted molecular contrast agent can be used successfully to cause lung adenocarcinomas to fluoresce during pulmonary surgery.
Shire plc and Parion Sciences, Inc. have announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults, with the opportunity for Parion to co-fund.
Diets with high amounts of whole grains may help achieve significant weight loss, and also reduce the risk of chronic diseases such as diabetes and cardiovascular disease, according to a team of Penn State researchers at University Park and the College of Medicine.
› Verified 7 days ago
Entity Name | Mark R Kobayashi Md Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1679727713 PECOS PAC ID: 8628131547 Enrollment ID: O20090120000216 |
News Archive
The 5-4 ruling says some closely held corporations cannot be forced to provide services that are at odds with the owners' religious beliefs.
More than 80,000 people undergo resection of a pulmonary tumor each year, and currently the only method to determine if the tumor is malignant is histologic analysis. A new study reports that a targeted molecular contrast agent can be used successfully to cause lung adenocarcinomas to fluoresce during pulmonary surgery.
Shire plc and Parion Sciences, Inc. have announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults, with the opportunity for Parion to co-fund.
Diets with high amounts of whole grains may help achieve significant weight loss, and also reduce the risk of chronic diseases such as diabetes and cardiovascular disease, according to a team of Penn State researchers at University Park and the College of Medicine.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Mark R Kobayashi, MD Plastic Surgery Division - Uci, Po Box 515072, Los Angeles, CA 90051-5072 Ph: (714) 456-6369 | Mark R Kobayashi, MD Uci Medical Center, 101 The City Drive South, Orange, CA 92868 Ph: (714) 456-8978 |
News Archive
The 5-4 ruling says some closely held corporations cannot be forced to provide services that are at odds with the owners' religious beliefs.
More than 80,000 people undergo resection of a pulmonary tumor each year, and currently the only method to determine if the tumor is malignant is histologic analysis. A new study reports that a targeted molecular contrast agent can be used successfully to cause lung adenocarcinomas to fluoresce during pulmonary surgery.
Shire plc and Parion Sciences, Inc. have announced they have entered into an agreement granting Shire exclusive worldwide rights to develop and commercialize P-321. Shire will lead development of P-321, an investigational epithelial sodium channel (ENaC) inhibitor for the potential treatment of dry eye disease in adults, with the opportunity for Parion to co-fund.
Diets with high amounts of whole grains may help achieve significant weight loss, and also reduce the risk of chronic diseases such as diabetes and cardiovascular disease, according to a team of Penn State researchers at University Park and the College of Medicine.
› Verified 7 days ago
Dr. James F Coleman Jr., MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1201 W La Veta Ave Ste 207, Orange, CA 92868 Phone: 714-288-8842 Fax: 714-288-8807 | |
Dr. Miles Pfaff, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 200 S Manchester Ave Ste 650, Orange, CA 92868 Phone: 714-456-3077 | |
Dr. Cathy Joyce Tang, M.D. Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 200 S Manchester Ave Ste 650, Orange, CA 92868 Phone: 714-456-3077 | |
Daniel S Urias, MD Plastic Surgery Medicare: Medicare Enrolled Practice Location: 1500 E Katella Ave Ste P, Orange, CA 92867 Phone: 714-844-6334 Fax: 714-464-8646 | |
Dr. Andres Taleisnik, MD Plastic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1310 W Stewart Dr Ste 410, Orange, CA 92868 Phone: 714-538-8549 Fax: 714-538-1547 | |
Arthur Hagop Salibian, MD Plastic Surgery Medicare: May Accept Medicare Assignments Practice Location: 1310 W Stewart Drive, Suite 211, Orange, CA 92868 Phone: 714-997-4848 Fax: 714-997-4847 | |
Nicole Conkling, MD Plastic Surgery Medicare: Medicare Enrolled Practice Location: 200 S Manchester Ave Ste 650, Orange, CA 92868 Phone: 714-456-3077 |